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The aim of this work was to test in vitro and in vivo the efficacy of the derivatives of 5-aminolevulinic acid (ALA): hexyl-ALA (He-ALA),
undecanoyl-ALA and R,S-2-(hydroximethyl)tetrahydropyranyl-ALA (THP-ALA) as pro-photosensitising agents. The compounds
were assayed in a cell line derived from a murine mammary tumour, in tumour explants and after injection of the cells into mice. In
vitro, undecanoyl-ALA and THP-ALA did not improve ALA efficacy in terms of porphyrin synthesis. On the other hand, half of the
amount of ALA is required to obtain the same plateau amount of photosensitiser from He-ALA. However, this plateau value cannot
be surpassed in spite of the four-times higher accumulation of ALA/He-ALA from the ALA derivative. This shows that He-ALA
conversion to porphyrins but not He-ALA entry to the cells is limiting. Employing ionic exchange chromatography, we found that 80%
of total uptake was He-ALA whereas only 20% was ALA. This suggests that the esterases, probably themselves regulated by the
heme pathway, are limiting the conversion of ALA derivatives into porphyrins. A similar situation occurs with THP-ALA. Tumour
explant porphyrin results correlate well with cell line data. However, i.p. injection of ALA derivatives to mice resulted in a lower
porphyrin concentration in the tumour when compared to the administration of equimolar amounts of ALA, indicating that there
should be retention of ALA derivatives either within the blood vessels in the initial phase of distribution and/or within the capillaries of
the tumour.
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5-Aminolevulinic acid (ALA) is the first intermediate in heme
biosynthesis and a precursor of protoporphyrin IX (PpIX).
Protoporphyrin IX is used as an endogenous photosensitiser in
photodynamic therapy (PDT) (Kennedy et al, 1990). The main
advantage of using PpIX relative to other photosensitisers is the
short half life of its photosensitising effects, which do not last
longer than 48h (Fukuda et al, 1992). 5-Aminolevulinic acid-
induced porphyrin fluorescence may also assist in the early
detection of some malignancies (Baumgartner et al, 1996).
The hydrophilic nature of the ALA molecule appears to limit its
penetration through the stratum corneum of the skin. Hence, ALA-
induced PpIX formation is often restricted to superficial tissue
layers because of both uneven and partial tissue distribution in the
deeper-lying or nodular lessions (Peng et al, 1995). More lipophilic
derivatives of ALA were expected to have better diffusing
properties, and, after their conversion into the parent ALA by
enzymatic hydrolysis, to reach a higher PpIX formation rate.
To induce higher PpIX formation and photosensitisation,
several chemical modifications both on the amino and carboxyl
groups of ALA have been made, from which different degrees of
photosensitisation were achieved (Casas and Batlle, 2002).
Factors involved in the uptake of the pro-drugs and release of
ALA are manifold: (a) diffusion rates through the tissues; (b)
uptake by the cell; and (c) liberation of ALA from the derivatives.
Owing to the multiple factors involved in final ALA availability,
differences between in vivo and in vitro efficiencies from the
different compounds used as pro-photosensitisers were expected
(Casas et al, 2001a, b; Perotti et al, 2002).
The aim of this work was to test in vitro and in vivo the efficacy
of the following ALA derivatives as pro-photosensitisers: hexyl-
ALA (He-ALA), undecanoyl-ALA and R,S-2-(hydroximethyl)tetra-
hydropyranyl-ALA (THP-ALA) in comparison with ALA in a
murine mammary tumour.
MATERIALS AND METHODS
Cell line and cell culture
Cell line LM3 (Werbajh et al, 1998) derived from the murine
mammary adenocarcinoma M3 was cultured in minimum essential
Eagle’s medium, supplemented with 2mML -glutamine, 40mg
gentamycinml
 1 and 5% foetal bovine serum (FBS), and incubated
at 371C in an atmosphere containing 5% CO2. Cells were used 48h
after plating.
Chemicals
5-Aminolevulinic acid was from Sigma Chemical Co. St. Louis,
MO, USA 5-Aminolevulinic acid derivatives were obtained as the
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shydrochloric salts. Hexyl-ALA and undecanoyl-ALA were synthe-
sised according to the method of Takeya (1992), by reacting ALA
with hexanol and undecanol, respectively, in the presence of
thionyl chloride. The mixture was stirred at 701C until ALA HCl
was completely dissolved, and the reaction was confirmed by TLC
(Cl2CH3:MeOH 9:1). The excess alcohol was evaporated under
high vacuum. After addition of diethylether, the HCl salts of the
ALA esters were allowed to crystallise at 41C. Yields ranged from
40 to 60%. R,S-ALA-2-(hydroximethyl) tetrahydropyranyl ester
was similarly obtained. The crude product was purified by flash
column cromatography on silica gel eluting with Cl2CH3/MeOH
mixtures. The yield was 20%. Purity of the synthesised compounds
was always higher than 95%, as established by TLC and NMR
techniques.
5-Aminolevulinic acid derivatives were dissolved in phosphate
buffer saline (PBS) immediately before use, and the resulting
solutions were sterilised by filtration through 0.21mm pore size
filters. Addition of either ALA or ALA derivatives to the cells did
not change the pH of the medium.
Porphyrin extraction from cells
Porphyrins accumulated within the cells were extracted twice with
5% HCl, leaving the cells standing for half an hour in the presence
of the acid at 371C. For media determinations, 5% HCl was added
and measured directly. These conditions proved to be the optimal
for total PpIX extraction. Excitation and emission wavelengths of
light producing the highest fluorescence were used (406 and
604nm, respectively). Protoporphyrin IX (Porphyrin Products,
Logan, UT, USA) was used as a reference standard.
5-Aminolevulinic acid and porphobilinogen (PBG)
determination in cells
We have previously found that THP-ALA, undecanoyl-ALA and
He-ALA content can be determined indistinguishably from ALA by
the method of Di Venosa et al (2003). Cells were seeded in 100mm
dishes. After 48h, medium was removed and cells were exposed for
3h to 0.6mM ALA or ALA derivatives in serum-free medium.
Afterwards, cells were washed four times with PBS and then 5%
TCA was added. After scrapping, the cells were centrifuged and the
supernatant was employed for ALA and PBG determination
following the method of Mauzerall and Granick (1956), slightly
modified as indicated. Briefly, for ALA determination, a con-
densation reaction was developed in the presence of acetyl acetone
and the resulting pyrroles were quantified by addition of the
Ehrlich’s reagent. 5-Aminolevulinic acid and ALA derivative
standards were condensed under similar conditions and thereafter
employed for calculations. For PBG determination, the Ehrlich’s
reagent was added to the deproteinised TCA supernatant. 5-
Aminolevulinic acid values were obtained by subtracting PBG
values from the total value of condensed pyrroles.
5-Aminolevulinic acid, He-ALA and THP-ALA separation
using ion-exchange column chromatography
Cells were plated in 100mm dishes. A pool of two dishes per point
was used. After 72h, the medium was removed and cells were
exposed for 3h to 0.6mM ALA or ALA derivatives in serum-free
medium. Afterwards, cells were washed four times with PBS and
5% TCA was added. After scrapping, the cells were centrifuged and
the content of two dishes was pooled. An aliquot of the each
supernatant was employed for ALA and PBG determination, as
described above. The rest of the supernatant was passed through a
column of Dowex 50 X 8 resin, as reported elsewhere (Di Venosa
et al, 2003). 5-Aminolevulinic acid was separated from ALA
derivatives, and the percentage of the total was calculated from the
total ALA after subtracting the PBG value.
Photodynamic therapy treatment in vitro
Cells seeded in six-well plates were incubated in serum-free
medium containing ALA or ALA derivatives; 3h later, irradiations
were performed. After irradiation, the medium was replaced by
ALA-free mediumþFBS, the cells were incubated for another 19h
and then tested for viability.
Light source
For PDT experiments, a bank of two fluorescent lamps (Osram L
36W/10) was used. The spectrum of light was between 400 and
700nm, with the highest radiant power at 600nm. The plates were
located at a distance of 60cm from the light source. Fluence rate
was measured with a Yellow Springs Kettering model 65 radio-
meter (Yellow Springs, OH, USA).
MTT viability assay
Phototoxicity and cell viability were documented by the MTT assay
(Denizot and Lang, 1986), a method based on the activity of
mitochondrial dehydrogenases, which will be functionally affected
by PDT in vitro (Hilf et al, 1984). Following appropriate
treatments, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium-
bromide (MTT) solution was added to each well in a concentration
of 0.5mgml
 1, and plates were incubated at 371C for 1h. The
resulting formazan crystals were dissolved by the addition of
DMSO and absorbance was read at 560nm.
Animals
Male BALB/c mice, 12 weeks old, weighing 20–25g were used.
They were provided with food (Purina 3, Molinos Rio de la Plata)
and water ad libitum. A suspension of 1.65 10
5 cells of the LM3
cell line was subcutaneously injected on the flanks of male BALB/c
mice. Experiments were performed at approximately day 20 after
implantation. Tumours of the same uniform size were employed
(1cm diameter). Animals received human care and were treated in
accordance with the guidelines established by the Animal Care and
Use Committee of the Argentine Association of Specialists in
Laboratory Animals (AADEALC), in full accord with the UK
Guidelines for the Welfare of animals in Experimental Neoplasia
(Workman et al, 1998).
5-Aminolevulinic acid administration
The hydrochloric salt of ALA and ALA derivatives was dissolved in
saline in a final volume of 0.15ml immediately before intraper-
itoneal (i.p.) injection.
Times of killing were chosen according to optimal ALA and He-
ALA conditions (Perotti et al, 2002), with the aim of correlating
ALA with porphyrin content at a certain time point.
Tumour porphyrin extraction
After ALA or ALA derivative injection, animals were killed. Before
killing, mice were injected with heparin (0.15ml, 1000UI) and after
killing they were perfused with 200ml of sterile saline. The tumour
samples were homogenised in a 4:1 solution of ethyl acetate:gla-
cial acetic acid mixture according to Batlle (1997). Briefly, the
mixtures were centrifuged for 30min at 3000g, and the super-
natants were added with an equal volume of 5% HCl. Extraction
with HCl was repeated until negative fluorescence in the organic
layer. The aqueous fraction was used for the determination of
porphyrins. For fluorometric determination, a Shimadzu RF-510
spectrofluorometer was used, with an emission wavelength at
604nm and an excitation wavelength at 406nm, employing PpIX
as a reference standard.
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tissue
Briefly, 100mg of tissue were homogenised in 1 M acetic acetate
buffer (pH 4.8); 5% TCA was added to deproteinise and samples
were centrifuged for 30min at 3000g. 5-Aminolevulinic acid and
PBG content were determined as described above, except for a
second centrifugation that was performed after ALA condensation.
Organ explant cultures
The explant tissue culture system developed by Polo et al (1988)
was used. Tumour explants of about 50mg were floated in petri
dishes in serum-free minimal essential Eagle’s medium, supple-
mented with 2mML -glutamine and gentamycin (40mgml
 1) and
incubated at 371C in presence of 0.6mM ALA or ALA derivatives
for 3h, washed with PBS and processed for porphyrin extraction,
as described above. The optimal conditions for incubation and
explant sizes were as determined in a previous work (Fukuda et al,
1989).
Statistical analysis
The unpaired t-test was used to establish the significance of
differences between groups. Differences were considered statisti-
cally significant when Po0.05. In vitro experiments: three
independent experiments, in triplicates. In vivo experiments: three
mice per group were employed.
RESULTS
Figure 1 shows the dependance of porphyrin synthesis on ALA or
ALA derivative concentration. We find saturation points at 0.3mM
ALA and THP-ALA, 0.15mM He-ALA and 0.075mM undecanoyl-
ALA. The maxima porphyrin synthesis from ALA, THP-ALA and
He-ALA is around 40mg/10
5 cells. Undecanoyl-ALA only produces
4.5mg/10
5 cells under the best conditions. Porphyrin synthesis
from ALA and THP-ALA exhibits a sigmoidal shape, showing a
sharp increase in porphyrin synthesis at 0.1mM ALA. On the
contrary, porphyrin synthesis increases gradually upon increasing
the hexyl and undecanoyl derivative concentration.
The time dependance of porphyrin synthesis in the presence of
ALA and ALA derivatives under saturating conditions is shown in
Figure 2. An almost linear increase is shown for porphyrin
synthesised from ALA, He-ALA and THP-ALA. A low amount of
porphyrins is formed from 0.3mM undecanoyl-ALA, and this
concentration could not be further increased due to intrinsic
toxicity at longer incubation times.
Figure 3 depicts dark toxicity and PDT toxicity, varying with
ALA or ALA derivative concentration. The only compound that is
intrinsically toxic to the cells without light is undecanoyl-ALA,
which is harmful at very low concentrations. At low doses, He-ALA
is more effective than ALA due to the threshold required for
porphyrin synthesis.
Figure 4 shows the PDT response driven by ALA and its
derivatives, varying with the light dose. The ALA and ALA
derivative concentrations employed produced maximal porphyrin
synthesis. We can observe that on increasing the light dose PDT
toxicity increases similarly for ALA, THP-ALA and He-ALA,
whereas for undecanoyl-ALA, a 40% decrease of viability is
observed at 0.3mM and concentrations above 0.3mM lead to
complete cell death, but due to intrinsic toxicity of the derivative
and not to the PDT effect.
Table 1 shows ALA and PBG accumulation in cells treated with
ALA or ALA derivatives. We can clearly see that ALA and/or He-
ALA accumulated from He-ALA is four times higher than ALA
accumulated from ALA. However, PBG accumulation is not higher
from He-ALA, and neither is porphyrin synthesis (see Figure 1)
due to the low conversion of He-ALA into ALA (only 20%). The
amount of ALA and/or THP-ALA accumulated from THP-ALA is
2.8 times higher than the amount formed by ALA, but only 40% is
converted into ALA, so that again PBG and porphyrin synthesis
remain the same. ALA and/or undecanoyl-ALA accumulated from
the former is very low and could not be separated by
chromatography.
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Figure 1 Porphyrin synthesis from ALA and ALA derivatives. Cells were
incubated for 3h in the presence of different amounts of ALA or its
derivatives. Intracellular porphyrins were determined fluorometrically and
relativised per number of cells present at the beginning of the experiment.
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Figure 2 Porphyrin synthesis as a function of incubation time in the
presence of ALA and derivatives. Cells were incubated during different
time periods in the presence of 1.2mM ALA, THP-ALA and He-ALA and
0.3mM undecanoyl-ALA in 24-well plates. Intracellular porphyrins were
determined fluorometrically and relativised per number of cells present at
the beginning of the experiment.
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sTable 2 shows tumour explant porphyrin synthesis from 0.6mM
ALA and ALA derivatives. Porphyrin synthesis from He-ALA and
THP-ALA is similar to that produced from ALA. Undecanoyl-ALA
porphyrin synthesis was five-fold lower, hardly above the basal
levels.
Table 3 shows tumour porphyrin synthesis after systemic
administration of equimolar concentrations of ALA and ALA
derivatives to mice. 5-Aminolevulinic acid is the best inducer of
porphyrin synthesis under these conditions, followed by THP-
ALA, He-ALA and undecanoyl-ALA. A much higher amount of
ALA than ALA derivatives reaches the tumour 10min after i.p.
administration. After 3h, the same amount of ALA is retained
within the tissue from ALA and from ALA derivatives.
DISCUSSION
I.p. injection to mice of the derivatives He-ALA and undecanoyl-
ALA resulted in porphyrin concentrations five-fold lower in
tumour when compared to equimolar amounts of ALA adminis-
tration. THP-ALA induced half the amount of porphyrins
produced by ALA. Concentration of the derivatives could not be
increased further because they were lethal to mice.
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Figure 3 Dark and PDT toxicity of ALA and ALA derivatives. Cells were
incubated for 3h in the presence of different amounts of ALA or its
derivatives in the dark (A) or exposed to 0.25 (B) and 0.4Jcm
 2 of light
(C). The MTT assay was performed after 19h. Cell survival is expressed as
a percentage of the control nonirradiated and exposed to ALA or
derivatives.
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Figure 4 Photodynamic therapy with ALA or ALA derivatives and the
dependance on light dose. Cells were incubated for 3h in the presence of a
fixed concentration of ALA (0.6mM), undecanoyl-ALA (0.3mM), THP-ALA
(0.6mM) or He-ALA (0.6mM) and exposed to a varying light dose. The
MTT assay was performed after 19h. Cell survival is expressed as a
percentage of the control nonirradiated and exposed to ALA or
derivatives.
Table 1 ALA and PBG accumulation in cells
pmol ALA or
ALA derivatives/10
5
cells
a
ALA (percentage
of ALA+ALA
derivative)
b
pmol
PBG/10
5
cells
Control 1.6270.07 ND 0.7570.03
ALA 13.0570.90 100% 1.570.11
He-ALA
a 42.4176.20 20% 1.771.3
Undecanoyl-ALA 3.1570.12 ND 0.870.04
THP-ALA 36.374.78 40% 2.0770.46
ALA and PBG were determined as described in Materials and methods after 3h
exposure to 0.6mM ALA or ALA derivatives.
aALA determinations correspond to the
ALA+ALA derivative intracellularly accumulated in the cells, without distinction
between ALA and its derivative. Controls correspond to basal levels of untreated
cells. ND¼nondetectable.
bDetermined by ionic exchange chromatography.
Table 2 Porphyrin synthesis in tumour explants incubated with ALA and
ALA derivatives
lg porphyrin/g tissue
Control 0.3370.02
ALA 5.1770.26
He-ALA 5.8370.38
Undecanoyl-ALA 1.1870.07
THP-ALA 5.5370.27
Tumour explants were incubated for 3h with 0.6mM ALA or ALA derivatives.
Porphyrins were extracted and determined as described in Materials and Methods.
Controls correspond to the tissue basal porphyrin levels.
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sWhen the LM3 cell line was exposed to undecanoyl-ALA, we
have found that toxicity was actually due to the release of the
alcohol after the esterase action (data not shown). However, in vivo
toxicity of He-ALA and undecanoyl-ALA may be provoked by a
different mechanism. When higher doses of He-ALA and
undecanoyl-ALA are used, mice die suddenly within the following
5min. Based on the observation that He-ALA induces a high
porphyrin synthesis in brain (Perotti et al, 2002), we had suspected
that He-ALA was neurotoxic; however, this cannot be applied to
undecanoyl-ALA because this ALA derivative produces negligible
amounts of porphyrins in brain (Casas et al, unpublished results).
Porphyrin synthesis from He-ALA and undecanoyl-ALA in vitro
increases linearly from the beginning of the concentration curves.
Instead, ALA and THP-ALA do not induce porphyrin synthesis up
to 0.1mM. This suggests that their incorporation mechanisms into
the cell are different, and that, whereas ALA and THP-ALA uptake
appear to need a threshold concentration, He-ALA uptake takes
place even at low concentrations. It has been shown that in LM3
cells ALA uptake occurs by both diffusion and active transport, the
latter presumably mediated by a member of the GAT family
transporters (Bermu ´dez Moretti et al, 2002). Here, we have
evidence that He-ALA and undecanoyl-ALA are incorporated by
a different transport system. Krieg et al (2002) studied the kinetics
of PpIX after exposure of human colonic cell lines and fibroblasts
to He-ALA and benzyl-ALA. They also found that detectable
amounts of PpIX already synthesised from these ALA esters were
formed much earlier than from ALA, showing that passive
diffusion happens much faster than active transport of ALA via
the beta transporters.
Similarly, from kinetic studies, Whitaker et al (2000) hypothe-
sised that pentyl-ALA is incorporated into pancreatoma cells at a
faster rate than ALA, indicating that esterases are not limiting
porphyrin synthesis and that the ester must be translocated by
rapid diffusion. Depending on the pro-drug, different transport
mechanisms would be operating to reach more quickly the
threshold ALA level required for inducing porphyrin biosynthesis.
It has been previously reported that long-chained ALA esters
tend to remain in the cell membrane, thus synthesising lower PpIX
(Kloek et al, 1998). However, we have found that in cells low
concentrations of undecanoyl-ALA (up to 0.1mM) lead to higher
porphyrin synthesis than that produced from ALA, although this
amount cannot be increased by increasing the ALA-ester
concentration above 0.1mM.
Ele ´ouet et al (2000) found that rat glial tumour cells exposed to
THP-ALA were more efficiently photosensitised than cells exposed
to equimolar ALA concentrations. The same authors have shown
that THP-ALA sensitised the cells at concentrations as low as
18mM. However, in our cells, THP-ALA was not found to be a
better pro-photosensitiser than ALA. We ascribe these differences
in PDT response to the different cell types. We might speculate
that different ALA esters may be incorporated into the cells by
different transport mechanisms and that these mechanisms may
vary for each cell type.
Half of the amount of ALA is required to obtain the same
plateau amount of photosensitiser from He-ALA. However, this
plateau value cannot be surpassed in spite of the four-times higher
accumulation of ALA/He-ALA from the ALA derivative. This
shows that He-ALA conversion to porphyrins but not He-ALA
entry to the cells is limiting. To test whether or not esterase
converts He-ALA into ALA, we separated ALA from He-ALA by
ionic exchange chromatography. We found that 80% of the total
compound was He-ALA, whereas only 20% was ALA. This means
that around 8.5pmol of ALA is available for porphyrin synthesis,
and that esterases are limiting ALA conversion into porphyrins. A
similar situation occurs with THP-ALA. Although 2.8 times more
ALA/THP-ALA is accumulated in the cells, only 40% is converted
into ALA. In other words, only 14pmol of ALA is available for
porphyrin synthesis. This might be linked to some kind of
regulation through the esterases, which would provide just the
amount of ALA to be employed for porphyrin synthesis, probably
by means of a product regulation. In this regard, we could
speculate that esterases could be ultimately be regulated by the
heme pathway. However, more data are needed to confirm this
hypothesis.
5-Aminolevulinic acid/undecanoyl-ALA accumulation from un-
decanoyl-ALA is very low and could not be separated by
chromatographic techniques, but in this case there is a good
correlation between ALA accumulation and porphyrin synthesis,
apparently being under nonsaturating conditions of the esterases.
In vitro experiments with tumour explants are keeping in line
with cell data. Employing 0.6mM of ALA and ALA esters,
porphyrin synthesis from ALA, He-ALA and THP-ALA is similar,
while porphyrin accumulation from undecanoyl-ALA is hardly
above basal levels. These results indicate a good correlation
between both in vitro models, which are markedly different from
in vivo data.
Hexyl-ALA has previously proved to considerably induce PpIX
synthesis in vitro but not in vivo. These surprisingly huge
differences between results obtained with cell lines and their
parental tumours may be ascribed to a large number of factors: (a)
diminished ability of He-ALA for crossing vascular structures to
reach tumoural cells, (b) retention of He-ALA in the interstitial
space and consequent limited availability to cell layers, (c)
differential expression and activity of esterases in the cell line as
compared to the parental tumour (Casas and Batlle, 2002).
Around 170nmol ALAg
 1 tissue is retained in the tumour after
ALA injection, whereas three to five times less ALA is accumulated
from ALA derivatives. However, after 3h the ALA concentration is
similar from all compounds. Although three times less ALA is
accumulated from He-ALA, when compared to ALA porphyrin
synthesis is five times lower; however, the rest of ALA is not
present at 3h. Distribution of He-ALA to other tissues is possible.
Protoporphyrin IX synthesis in vitro does not reflect at all the
efficiency found in vivo, neither ALA nor ALA derivative
accumulation in vitro correlates with in vivo data, demonstrating
the complexity and difficulty for extrapolating results from in vitro
to in vivo models. The data suggest that after ALA or ALA ester i.p.
injection, retention of ALA derivatives either within the blood
vessels in the initial phase of distribution or/and within the
capillaries of the tumour is playing an important role in the
availability of ALA.
It is clear from the state of the art that the relevance of using
ALA derivatives lies in the possibility of decreasing ALA derivative
concentrations to reach equal porphyrin synthesis, and gaining
selectivity, without enhancing ALA accumulation. Our findings
underline the importance of working with ALA derivatives under
nonsaturating conditions of the esterase activities and/or heme
pathway. Further studies on the esterase saturation points and
their regulation will be the subject of future work.
Table 3 Tumour porphyrin synthesis from ALA and ALA derivatives
after systemic administration to mice and ALA content
nmol ALA or
ALA derivatives/g
tissue at 10min
nmol ALA or
ALA derivatives/g
tissue at 3h
nmol
porphyrins/g
tissue at 3h
Control 12.570.9 12.570.9 0.3670.05
ALA 170.278.4 15.1175.1 15.971.12
He-ALA 56.3710.3 12.971.5 3.1170.42
Undecanoyl-ALA 28.273.1 11.273.4 2.6470.23
THP-ALA 37.075.2 17.872.8 8.8370.95
In all, 3.3mg ALA, 5mg He-ALA, 6.3mg undecanoyl-ALA and 5.2mg THP-ALA were
administrated i.p. to mice. After 10min, the ALA content was determined and after
3h ALA and porphyrins were quantified in tumour. PBG levels at 10min and 3h
were undetectable.
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